Studi in Silico Lima Senyawa Aktif Sebagai Penghambat Protein Virus Dengue
Downloads
Downloads
Henchal EA, Putnak JR. The dengue viruses. Clinical Microbiology Review. 1990 Oct;3(4):376–96.
Alen MMF, Schols D. Dengue virus entry as target for antiviral therapy. Journal of Tropical Medicine. 2012;2012:1-13.
Luo D, Xu T, Hunke C, Gruber G, Vasudevan SG, Lescar J. Crystal structure of the NS3 protease-helicase from dengue virus. Journal of Virology. 2008 Jan;82(1):173–83.
Wang CC, Huang ZS, Chiang PL, Chen CT, Wu HN. Analysis of the nucleoside triphosphatase, RNA triphosphatase, and unwinding activities of the helicase domain of dengue virus NS3 protein. FEBS Letters. 2009 Feb;583(4):691–6.
Steinmann J, Buer J, Pietschmann T, Steinmann E. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. British Journal of Pharmacology. 2013 Mar;168(5):1059–73.
Wang RR, Gao YD, Ma CH, Zhang XJ, Huang CG, Huang JF, et al. Mangiferin, an anti-HIV-1 agent targeting protease and effective against resistant strains. Molecules. 2011 May;16(5):4264–77.
Wu W, Li R, Li X, He J, Jiang S, Liu S, et al. Quercetin as an antiviral agent inhibits influenza a virus (IAV) Entry. Viruses. 2015 Dec;8(1):1-18.
Carneiro BM, Batista MN, Braga ACS, Nogueira ML, Rahal P. The green tea molecule EGCG inhibits Zika virus entry. Virology. 2016 Sep;496:215–8.
Flobinus A, Taudon N, Desbordes M, Labrosse B, Simon F, Mazeron M-C, et al. Stability and antiviral activity against human cytomegalovirus of artemisinin derivatives. The Journal of Antimicrobial Chemotherapy. 2014 Jan;69(1):34–40.
Roy S, He R, Kapoor A, Forman M, Mazzone JR, Posner GH, et al. Inhibition of human cytomegalovirus replication by artemisinins: effects mediated through cell cycle modulation. Antimicrobial Agents and Chemotherapy. 2015 Jul;59(7):3870–9.
Isnawati A, Adelina R. Studi docking molekuler catechin gallate, epicatechin gallate, gallocatechin gallate, dan epigallocatechin gallate sebagai obat dislipidemia. Jurnal Kefarmasian Indonesia. 2015;5(1):25-32.
Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Current Computer Aided Drug Design. 2011 Jun;7(2):146–57.
Chang J, Schul W, Butters TD, Yip A, Liu B, Goh A, et al. Combination of alpha-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Research. 2011 Jan;89(1):26–34.
Wahala WMPB, Donaldson EF, Alwis R De, Loper MAA, Baric RS, Silva AM De. Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses. 2010;6(3):1–10.
Perera R, Kuhn RJ. Structural proteomics of dengue virus. Current Opinion in Microbiology. 2008 Aug;11(4):369–77.
Henderson BR, Saeedi BJ, Campagnola G, Geiss BJ. Analysis of RNA binding by the dengue virus NS5 RNA capping enzyme. PLoS One. 2011 Oct;6(10):1-9.
Christian EA, Kahle KM, Mattia K, Puffer BA, Pfaff JM, Miller A, et al. Atomic-level functional model of dengue virus envelope protein infectivity. Proceeding of The National Academy Sciences. 2013;110(46):1–6.











